Ibnsina Pharma results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements.
Net profit72.55 millionEGP · +22.2% vs the same period a year earlier
Total assets15.32 billionEGP · +23.4% vs the same period a year earlier
Shareholders' equity1.33 billionEGP · −11.8% vs the same period a year earlier
Operating cash flow-542 millionEGP · +36.4% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q1 2023 was about 72.55 million EGP, up +22.2% from 59.38 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 15.32 billion EGP, and shareholders' equity about 1.33 billion EGP.
- Operating cash flow for Q1 2023 was negative at 542 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit72.55 million59.38 million+22.2%
Gross profit575 million396 million+45.2%
Total assets15.32 billion12.42 billion+23.4%
Total liabilities13.99 billion10.91 billion+28.2%
Shareholders' equity1.33 billion1.51 billion−11.8%
Total liabilities and equity15.32 billion12.42 billion+23.4%
Operating cash flow-542 million-852 million+36.4%
Investing cash flow-52.53 million-576 million+90.9%
Financing cash flow621 million1.2 billion−48.4%
Net change in cash26.41 million-226 million+111.7%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy